Transactions
3
Insider / UNITED THERAPEUTICS Corp
Giltner Richard
Director at UNITED THERAPEUTICS Corp
- Company
- UNITED THERAPEUTICS Corp
- Ticker
- UTHR
- First filing on record
- July 13, 2026
- Latest trade on record
- July 22, 2026
- SEC filings
- EDGAR ↗
Giltner Richard, Director at UNITED THERAPEUTICS Corp, has disclosed 3 transactions in UTHR since July 13, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed July 23, 2026, 1 day after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
3.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Giltner Richard reported 3 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 2 | 2,620 | — |
| A | Grant or award | 1 | 760 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| UTHR | Other A | July 22, 2026 | July 23, 2026 | 1d | 760 | — | — | derivative | Form 4 ↗ | |
| UTHR | Option / conversion M | July 9, 2026 | July 13, 2026 | 4d | 1,310 | — | — | derivative | Form 4 ↗ | |
| UTHR | Option / conversion M | July 9, 2026 | July 13, 2026 | 4d | 1,310 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 23, 2026 | Form 4 | 0001460472-26-000002 | 1 | published | EDGAR ↗ |
| July 13, 2026 | Form 4 | 0001460472-26-000001 | 2 | published | EDGAR ↗ |
Other insiders at UNITED THERAPEUTICS Corp
- ROTHBLATT MARTINE A Chairperson & CEO 2,558 rows
- EDGEMOND JAMES CFO AND TREASURER 466 rows
- BENKOWITZ MICHAEL PRESIDENT AND COO 287 rows
- MAHON PAUL A EVP & GENERAL COUNSEL 282 rows
- CAUSEY CHRISTOPHER Director 18 rows
- MALCOLM JAN Director 13 rows
- Thompson Tommy G Director 13 rows
- PATUSKY CHRISTOPHER Director 12 rows
- Mesa Nilda Director 10 rows
- Olian Judy D. Director 9 rows
Everyone on file, with contracts and lobbying under the company's name: UNITED THERAPEUTICS Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 3 | July 13, 2026 | July 23, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.